Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESIST-NPC
NCT02065362Phase 1Active, not recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Feb 2015
- Primary completion
- Mar 2017
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of DNR.NPC-specific T cells in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity at 8 weeks. Started Feb 2015; status: active, not recruiting.
02
Drugs
DNR.NPC-specific T cells
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02065362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065362.